The European Medicines Agency (EMA) has published its 2016 Annual Report. The report focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life.
In 2016, the Agency recommended a marketing authorisation for:
- 81 medicines for human use, including 27 new active substances
- 11 medicines from the veterinary side were recommended for approval, including six new active substances
As a result of the safety monitoring of all medicines marketed in the European Union (EU), the product information for over 300 medicines for human use was updated on the b
asis of new safety data.
This document also contains three interviews with stakeholders and EMA representatives on topics of major interest :
Vaccine hesitancy – a threat to public health;
Creating an agile organisation for the 21st century;
How to reinforce surveillance of antimicrobial consumption.
The last part of the report provides a large amount of data and figures that illustrate the work of EMA and its impact.
Please click on the following links for more info:
